Jazz Pharma Announces Executive Changes

Ticker: JAZZ · Form: 8-K · Filed: Jul 10, 2025 · CIK: 1232524

Jazz Pharmaceuticals PLC 8-K Filing Summary
FieldDetail
CompanyJazz Pharmaceuticals PLC (JAZZ)
Form Type8-K
Filed DateJul 10, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: executive-changes, personnel, compensation

Related Tickers: JAZZ

TL;DR

Jazz Pharma C-suite shuffle: CMO out, new CMO in. Compensation details also filed.

AI Summary

Jazz Pharmaceuticals plc announced on July 8, 2025, changes in its executive team, including the appointment of a new Chief Medical Officer, Dr. Robert I. Smith, and the departure of its former Chief Medical Officer, Dr. Karen M. Smith. The company also reported on executive compensation arrangements.

Why It Matters

Changes in key executive positions can signal shifts in company strategy, research and development focus, or operational direction, potentially impacting future performance.

Risk Assessment

Risk Level: medium — Executive changes can introduce uncertainty regarding leadership stability and strategic direction.

Key Players & Entities

FAQ

Who has been appointed as the new Chief Medical Officer?

Dr. Robert I. Smith has been appointed as the new Chief Medical Officer.

Who is the former Chief Medical Officer that has departed?

Dr. Karen M. Smith is the former Chief Medical Officer who has departed.

What is the effective date of the reported events?

The earliest event reported is dated July 8, 2025.

What type of filing is this?

This is a Form 8-K Current Report filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Where is Jazz Pharmaceuticals plc incorporated?

Jazz Pharmaceuticals plc is incorporated in Ireland.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on July 10, 2025 by Dr. Robert I. Smith regarding Jazz Pharmaceuticals plc (JAZZ).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing